Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
XU, Chun-Fang, BING, Nan X, RAGONE, Leigh J, WHITTAKER, John C, SPRAGGS, Colin F, CARDON, Lon R, MOOSER, Vincent E, PANDITE, Lini N, BALL, Howard A, RAJAGOPALAN, Dilip, STERNBERG, Cora N, HUTSON, Thomas E, DE SOUZA, Paul, XUE, Zhengyu G, MCCANN, Lauren, KING, Karen S
Published in Journal of clinical oncology (20.06.2011)
Published in Journal of clinical oncology (20.06.2011)
Get full text
Journal Article
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies
MORGAN, Bruno, THOMAS, Anne L, MIETLOWSKI, William, FUXIUS, Stefan, UNGER, Clemens, O'BYRNE, Ken, HENRY, Andrew, CHERRYMAN, Graham R, LAURENT, Dirk, DUGAN, Margaret, MARME, Dieter, STEWARD, William P, DREVS, Joachim, HENNIG, Juergen, BUCHERT, Martin, JIVAN, Asvina, HORSFIELD, Mark A, MROSS, Klauss, BALL, Howard A, LEE, Lucy
Published in Journal of clinical oncology (01.11.2003)
Published in Journal of clinical oncology (01.11.2003)
Get full text
Journal Article
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
Li, Tianhong, LoRusso, Patricia, Maitland, Michael L, Ou, Sai-Hong Ignatius, Bahceci, Erkut, Ball, Howard A, Park, Jung Wook, Yuen, Geoffrey, Tolcher, Anthony
Published in Journal of hematology and oncology (10.03.2016)
Published in Journal of hematology and oncology (10.03.2016)
Get full text
Journal Article
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer
Janku, Filip, LoRusso, Patricia, Mansfield, Aaron S., Nanda, Rita, Spira, Alexander, Wang, Tianli, Melhem-Bertrandt, Amal, Sugg, Jennifer, Ball, Howard A.
Published in Investigational new drugs (01.10.2021)
Published in Investigational new drugs (01.10.2021)
Get full text
Journal Article
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
Yamamoto, Noboru, Ryoo, Baek-Yeol, Keam, Bhumsuk, Kudo, Masatoshi, Lin, Chia-Chi, Kunieda, Futoshi, Ball, Howard A., Moran, Diarmuid, Komatsu, Kanji, Takeda, Kentaro, Fukuda, Musashi, Furuse, Junji, Morita, Satoshi, Doi, Toshihiko
Published in Investigational new drugs (01.04.2020)
Published in Investigational new drugs (01.04.2020)
Get full text
Journal Article
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
Benson, 3rd, Al B, Kiss, Igor, Bridgewater, John, Eskens, Ferry A L M, Sasse, Carolyn, Vossen, Sandra, Chen, Jihong, Van Sant, Chip, Ball, Howard A, Keating, Anne, Krivoshik, Andrew
Published in Clinical cancer research (15.10.2016)
Published in Clinical cancer research (15.10.2016)
Get full text
Journal Article
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
Plummer, Ruth, Madi, Ayman, Jeffels, Melinda, Richly, Heike, Nokay, Bahar, Rubin, Stephen, Ball, Howard A., Weller, Steve, Botbyl, Jeffrey, Gibson, Diana M., Scheulen, Max E.
Published in Cancer chemotherapy and pharmacology (01.01.2013)
Published in Cancer chemotherapy and pharmacology (01.01.2013)
Get full text
Journal Article
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors
Heath, Elisabeth I., Infante, Jeffrey, Lewis, Lionel D., Luu, Thehang, Stephenson, Joe, Tan, Antoinette R., Kasubhai, Saifuddin, LoRusso, Patricia, Ma, Bo, Suttle, A. Benjamin, Kleha, Joseph F., Ball, Howard A., Dar, Mohammed M.
Published in Cancer chemotherapy and pharmacology (01.03.2013)
Published in Cancer chemotherapy and pharmacology (01.03.2013)
Get full text
Journal Article
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors
Burris, 3rd, Howard A, Dowlati, Afshin, Moss, Rebecca A, Infante, Jeffrey R, Jones, Suzanne F, Spigel, David R, Levinson, Kelly T, Lindquist, Diana, Gainer, Shelby D, Dar, Mohammed M, Suttle, A Benjamin, Ball, Howard A, Tan, Antoinette R
Published in Molecular cancer therapeutics (01.08.2012)
Published in Molecular cancer therapeutics (01.08.2012)
Get full text
Journal Article
Stereoselective Preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a Potent and Orally Active Dual Neurokinin NK1/NK2 Receptor Antagonist
Gerspacher, Marc, Lewis, Christine, Ball, Howard A, Howes, Colin, Subramanian, Natarajan, Ryffel, Karin, Fozard, John R
Published in Journal of medicinal chemistry (31.07.2003)
Published in Journal of medicinal chemistry (31.07.2003)
Get full text
Journal Article
Effect of P‐glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine
Drewe, Jürgen, Ball, Howard A., Beglinger, Christoph, Peng, Bin, Kemmler, Andreas, Schächinger, Hartmut, Haefeli, Walter E.
Published in British journal of clinical pharmacology (01.09.2000)
Published in British journal of clinical pharmacology (01.09.2000)
Get full text
Journal Article
Dual neurokinin NK1/NK2 antagonists : N-[(R, R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis( trifluoromethyl)benzamides and 3-[N'-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N'-methylhydrazino]-N-[(R)-2- oxo-azepan-3-yl]propionamides
GERSPACHER, Marc, VECCHIA, Luigi La, RYFFELA, Karin, BALL, Howard A, MAH, Robert, VON SPRECHER, Andreas, ANDERSON, Gary P, SUBRAMANIAN, Natarajan, HAUSER, Kathleen, BAMMERLIN, Heinrich, KIMMEL, Sabine, PAWELZIK, Viviane
Published in Bioorganic & medicinal chemistry letters (03.12.2001)
Published in Bioorganic & medicinal chemistry letters (03.12.2001)
Get full text
Journal Article
Biphenyl derivatives as novel dual NK1/NK2-Receptor antagonists
MAH, Robert, GERSPACHER, Marc, VON SPRECHER, Andreas, STUTZ, Stefan, TSCHINKE, Vincenzo, ANDERSON, Gary P, BERTRAND, Claude, SUBRAMANIAN, Natarajan, BALL, Howard A
Published in Bioorganic & medicinal chemistry letters (19.08.2002)
Published in Bioorganic & medicinal chemistry letters (19.08.2002)
Get full text
Journal Article
Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial
Patnaik, Amita, LoRusso, Patricia, Ball, Howard A., Bahceci, Erkut, Yuen, Geoffrey, Papadopoulos, Kyriakos P., Kittaneh, Muaiad, Tolcher, Anthony W.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design
Maitland, Michael L., Ou, Sai-Hong Ignatius, Tolcher, Anthony W., LoRusso, Patricia, Bahceci, Erkut, Ball, Howard A, Park, Jung Wook, Yuen, Geoff, Pesco Koplowitz, Luana, Li, Tianhong
Published in Journal of clinical oncology (20.05.2014)
Published in Journal of clinical oncology (20.05.2014)
Get full text
Journal Article
Abstract A165: Result of a phase 1 (dose-escalation stage), first-in-human study of ASP5878, an oral FGFR inhibitor, in patients with advanced solid tumors
Shimizu, Toshio, Doi, Toshihiko, Yamamoto, Noboru, Murakami, Haruyasu, Furuse, Junji, Kawai, Koji, Nishiyama, Hiroyuki, Morita, Satoshi, Takahashi, Shunji, Bahceci, Erkut, Steinberg, Joyce, Ball, Howard A., Kunieda, Futoshi, Takeda, Kentaro, Kita, Aya, Takeshita, Shigeru
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article